A cannabis product called delta-8 was made legal when the 2018 Farm Bill legalized hemp. But unlike its cousin CBD, delta-8 has psychoactive properties. And the FDA warns it has “serious health risks.” The agency has received more than 100 reports of bad reactions among people who consumed it.
Sales of formulas designed for toddlers increased in recent years, but health experts warn parents that, generally, once children reach their 1st birthday, they are fine with cow or plant milk and don’t need the expensive, high-calorie products. And doctors say toddler formula should not be given to infants.
California and New York would be the first states to require anyone under 18 to obtain prescriptions to purchase over-the-counter weight loss products, which some research has linked to eating disorders.
With fears of a winter surge looming, government agencies have authorized and encouraged vaccination with a newly formulated booster. But the science to support that decision remains inconclusive.
Lori McClintock, the wife of U.S. Rep. Tom McClintock of California, died after ingesting white mulberry leaf, according to the Sacramento County coroner. The plant is generally considered safe and is used in herbal remedies that claim to lower blood sugar, boost weight loss, and combat high cholesterol. Her death highlights the potential dangers of dietary supplements.
President Joe Biden has signed the Inflation Reduction Act and Congress is gone until after Labor Day. But the administration and lawmakers left lots of health policy achievements behind, including new rules to facilitate the sale of over-the-counter hearing aids and a potential reorganization of the Centers for Disease Control and Prevention. Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s Julie Rovner to discuss these issues and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
Paxlovid has eclipsed other available therapies for preventing life-threatening covid symptoms in high-risk patients. But even as doctors praise its effectiveness, many say they have unanswered questions about prescribing the drug and want more and better data about it.
Families affected by ultra-rare diseases are starting their own companies to speed the development of treatments for their kids, venturing into territory that traditional drugmakers deem too risky.
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when — not if —the old ones fail.
A rapidly changing landscape for abortion has left patients, providers, employers, and lawmakers alike wondering what is and is not legal and what to do next. Meanwhile, Democrats in Congress have resumed negotiations on legislation to lower drug prices and, potentially, continue expanded insurance subsidies for the Affordable Care Act. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
